TabletsClinical Overview
Trimetazidine Dihydrochloride is a myocardial metabolic anti-ischemic agent. It selectively inhibits the enzyme 3-ketoacyl-coenzyme A thiolase (3-KAT) in cardiac mitochondria, suppressing fatty acid beta-oxidation and shifting energy metabolism towards glucose oxidation. Glucose oxidation requires less oxygen consumption per unit of ATP produced, preserving myocardial cellular high-energy phosphate (ATP and phosphocreatine) levels during ischemia without altering heart rate, blood pressure, or coronary hemodynamics. Indicated as add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris inadequately controlled by or intolerant to first-line therapies.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily, one tablet in the morning and one in the evening with meals, swallowed with a glass of water. Modified-release tablets must be swallowed whole without chewing or crushing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash. Rare/Severe: Drug-induced Parkinsonian symptoms (tremors, akathisia, gait instability, rigidity), reversible upon discontinuation; restless legs syndrome, thrombocytopenia, and agranulocytosis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in Parkinson's disease, parkinsonian symptoms, tremors, and severe renal impairment (CrCl < 30 mL/min). Discontinue permanently if parkinsonian movement disorders occur. Not an abortive treatment for acute angina attacks.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
